A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents

BACKGROUND: Fibroblast growth factor (FGF) 21 was reported to be induced by different injurious agents, including chronic hepatitis C (CHC) virus, affecting the liver. The aims of this study were to evaluate the FGF21 levels in CHC patients before and after the treatment with direct-acting antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales: El Sagheer, Ghada M, Ahmad, Asmaa K, Abd-ElFattah, Aliaa S, Saad, Zienab M, Hamdi, Lamia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204854/
https://www.ncbi.nlm.nih.gov/pubmed/30425548
http://dx.doi.org/10.2147/CEG.S173484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204854/
https://www.ncbi.nlm.nih.gov/pubmed/30425548
http://dx.doi.org/10.2147/CEG.S173484

Ejemplares similares